Last reviewed · How we verify

AZD4017 — Competitive Intelligence Brief

AZD4017 (AZD4017) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: NHE1 inhibitor. Area: Cardiovascular.

phase 2 NHE1 inhibitor NHE1 Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

AZD4017 (AZD4017) — AstraZeneca. AZD4017 is a small molecule inhibitor of the sodium-hydrogen exchanger 1 (NHE1).

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
AZD4017 TARGET AZD4017 AstraZeneca phase 2 NHE1 inhibitor NHE1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (NHE1 inhibitor class)

  1. AstraZeneca · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). AZD4017 — Competitive Intelligence Brief. https://druglandscape.com/ci/azd4017. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: